This is a non-core endpoint: only basic statistics are computed.
See its core counterpart C3_ENDOCRINE_EXALLC for full statistics.
Malignant neoplasm of endocrine gland
DOID EFO MESH SNOMED Endpoint Browser
C3_ENDOCRINE
endocrine neoplasm: A benign or malignant neoplasm arising from the epithelial cells of an endocrine organ. Representative examples include pituitary gland adenoma, pituitary gland carcinoma, thyroid gland carcinoma, carcinoid tumor, and neuroendocrine carcinoma.
Endpoint definition
↥
FinnGen phenotype data
429209 individuals
Apply sex-specific rule None
429209
Check conditions None
429209
Check pre-conditions, main-only, mode, registry filters None
0 out of 7 registries used, show all original rules.
0
Check minimum number of events None
0
Remove individuals based on genotype QC
2029
C3_ENDOCRINE
Control definitions
Controls for this endpoint are individuals that are not cases.
Extra metadata
Level in the ICD hierarchy
2
First used in FinnGen datafreeze
DF4
No data for upset plot.
No data for upset table.
Similar endpoints
↥List of similar endpoints to
Malignant neoplasm of endocrine gland
based on the number of shared cases.
Broader endpoints:
- Malignant neoplasm of endocrine gland (controls excluding all cancers)
- Malignant neoplasm
- Malignant neoplasm (controls excluding all cancers)
- Malignant neoplasm, wide definition for exclusion
- Malignant neoplasm, wide definition for exclusion (controls excluding all cancers)
Narrower endpoints:
Summary Statistics
↥Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 2029 | 1476 | 553 |
| Unadjusted prevalence (%) | 0.49 | 0.64 | 0.30 |
| Mean age at first event (years) | 49.99 | 48.05 | 55.16 |
Mortality
Not a core endpoint, no data to show.
Age distribution of first events
Year distribution of first events
Cumulative Incidence
Not a core endpoint, no data to show.
Correlations
↥
Index endpoint: C3_ENDOCRINE – Malignant neoplasm of endocrine gland
GWS hits:
Survival analyses between endpoints
↥Not a core endpoint, no data to show.
Drugs most likely to be purchased after Malignant neoplasm of endocrine gland
↥Endpoint not on priority list, no data to show.